Please login to the form below
Data by
15
Revenue 2014Bristol-Myers Squibb
The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Bristol-Myers Squibb's 2013 sales performance.
EP downgrades long-term sales projections for pharma
It expects Merck &Co's Keytruda (pembrolizumab) to topple Bristol-Myers Squibb's Opdivo (nivolumab) as the top-selling drug in that class by that year.
Taking a lean and careful approach
Cerrone, who has a track record of seeding new enterprises, co-founded Synergy and also orchestrated the sale of Inhibitex to Bristol-Myers Squibb for $2.5bn.
Merck suspends two Keytruda trials after patient deaths
It is chasing market leader Opdivo (nivolumab) from Bristol-Myers Squibb, which brought in $3.77bn and $1.13bn, respectively.
AbbVie appoints new general managers
Fumoleau has also served the likes of Bristol-Myers Squibb in various positions in marketing and sales and Astra-Zeneca’s director of oncology.
Ferring Pharmaceuticals promotes Aaron Graff
Prior to joining Ferring, Graff worked at Bristol-Myers Squibb for over 17 years in a variety of sales, marketing and commercial operations management positions.
| Global revenue 2014 |
|---|
| 1: Novartis |
| 2: Pfizer |
| 3: Roche |
| 4: Sanofi |
| 5: Merck & Co. |
| 6: Johnson & Johnson |
| 7: GlaxoSmithKline |
| 8: AstraZeneca |
| 9: Gilead Sciences |
| 10: Takeda |
| 11: AbbVie |
| 12: Amgen |
| 13: Teva |
| 14: Lilly |
| 15: Bristol-Myers Squibb |
| 16: Bayer |
| 17: Novo Nordisk |
| 18: Astellas |
| 19: Boehringer Ingelheim |
| 20: Actavis |
| 21: Otsuka |
| 22: Daiichi Sankyo |
| 23: Biogen Idec |
| 24: Baxter |
| 25: Merck KGaA |
| US revenue 2014 |
|---|
| 1: Gilead Sciences |
| 2: Johnson & Johnson |
| 3: Pfizer |
| 4: Roche |
| 5: Novartis |
| 6: Amgen |
| 7: Merck & Co. |
| 8: Sanofi |
| 9: AbbVie |
| 10: Actavis |
| 11: AstraZeneca |
| 12: GlaxoSmithKline |
| 13: Lilly |
| 14: Bristol-Myers Squibb |
| 15: Novo Nordisk |
| Oncology revenue 2014 |
|---|
| 1: Roche |
| 2: Novartis |
| 3: Celgene |
| 4: Johnson & Johnson |
| 5: Bristol-Myers Squibb |
| 6: Lilly |
| 7: Takeda |
| 8: AstraZeneca |
| 9: Merck & Co. |
| 10: Amgen |
| 11: Pfizer |
| 12: Astellas |
| 13: Bayer |
| 14: Otsuka |
| 15: Sanofi |
| 16: Merck KGaA |
| 17: Eisai |
| 18: AbbVie |
| 19: Pharmacyclics |
| 20: Incyte |
| Immunology revenue 2014 |
|---|
| 1: AbbVie |
| 2: Johnson & Johnson |
| 3: Pfizer |
| 4: Amgen |
| 5: Merck & Co. |
| 6: Astellas |
| 7: Roche |
| 8: Novartis |
| 9: Bristol-Myers Squibb |
| 10: Mitsubishi Tanabe |
| 11: UCB |
| 12: Hisamitsu |
| 13: Daiichi Sankyo |
| 14: Takeda |
| CNS revenue 2014 |
|---|
| 1: Pfizer |
| 2: Biogen Idec |
| 3: Novartis |
| 4: Otsuka |
| 5: Teva |
| 6: Johnson & Johnson |
| 7: Lilly |
| 8: Merck KGaA |
| 9: AstraZeneca |
| 10: Shire |
| 11: Bristol-Myers Squibb |
| 12: UCB |
| 13: Lundbeck |
| 14: Eisai |
| 15: GlaxoSmithKline |
| 16: Sanofi |
| 17: Mylan |
| 18: Indivior |
| 19: Actavis |
| 20: Bayer |
| Cardiovascular revenue 2014 |
|---|
| 1: AstraZeneca |
| 2: Sanofi |
| 3: Merck & Co. |
| 4: Daiichi Sankyo |
| 5: Pfizer |
| 6: Novartis |
| 7: Bayer |
| 8: Takeda |
| 9: Boehringer Ingelheim |
| 10: Astellas |
| 11: Actelion |
| 12: Johnson & Johnson |
| 13: Shionogi |
| 14: United Therapeutics |
| 15: Bristol-Myers Squibb |
| 16: Gilead Sciences |
| 17: Otsuka |
| 18: Roche |
| 19: Lilly |
| 20: The Medicines Company |
| Biologic revenue 2014 |
|---|
| 1: Roche |
| 2: Amgen |
| 3: Novo Nordisk |
| 4: AbbVie |
| 5: Sanofi |
| 6: Johnson & Johnson |
| 7: Pfizer |
| 8: Merck & Co. |
| 9: Lilly |
| 10: Biogen Idec |
| 11: Merck KGaA |
| 12: GlaxoSmithKline |
| 13: Bristol-Myers Squibb |
| 14: Novartis |
| 15: Bayer |
Data by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
Featured jobs
- Account Director - Healthcare Advertising - London
-
£50000 - £68000
- 6-12 MONTH FREELANCE OPPORTUNITY - ACCOUNT DIRECTOR or SENIOR AC...
-
SUPERB DAY RATE AVAILABLE
-
Principal Medical Writer
-
Great salary and benefits
-
Account Director - Med Comms
-
Great salary and benefits
-
Head of Marketing Insulin
-
Competitive Salary
-
Director – Healthcare PR/ Policy
-
Salary TBC
- Account Manager, Healthcare PR, Global and UK
-
£33, 000 – £40, 000
- Senior Director, Healthcare PR, Home Counties
-
Competitive
-
*Design Manager*
-
Competitive Salary
-
Scientific Director
-
£70, 000 - £85, 000
- Senior Corporate Communications Manager
-
Competitive Salary
- Account Director or Senior Account Director, Healthcare Advertis...
-
£55, 000 - £65, 000 benefits
- FREELANCE *Client Service/ Project Manager*
-
Competitive Salary
- Account Manager, Medical Communications
-
£30, 000-£40, 000
- Senior Account Manager – Healthcare PR
-
Salary TBC
-
Brand Communications Manager
-
A competitive salary plus bonus
-
*Multi-Channel Creative Designer*
-
Competitive Salary
-
Senior Medical Writer
-
Great salary and benefits
Subscribe to our email news alerts
- Sanofi continues pharma's trend of ditching the corporate blog
- Bayer wins FDA approval for MS electronic autoinjector and app
- Warning sounded on pharma's long-term sales prospects
- Facing the new wave of biosimilars
- Sandoz joins Europe's MabThera biosimilar push
- FDA panel backs CV claims for Novo Nordisk's Victoza
- The new pharma marketing playbook
- PEGASUS SHOWREEL 2017
- Alzheon says data backs potential of Alzheimer's candidate
- Shift to value-based medicine will boost mHealth uptake
- Ashfield to host global webinar on Patient Service Team on 10 July
- Pharma needs to evolve from customer-centricity to stakeholder-centricity
PMHub
SEVEN STONES
Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....
Latest intelligence
- The new pharma marketing playbook
- Learn about the 5 areas that must be in your pharma marketing playbook...
- Pharma needs to evolve from customer-centricity to stakeholder-centricity
- Customer-centricity and patient-centricity is no longer enough for pharma sales and marketing strategies as digital promises better customer experiences for all pharma stakeholders....
- 5 health behavioural factors to incorporate in your marketing
- Achieve real health behaviour change by including these elements in your pharmaceutical marketing....
Quick links
Infographics
